Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer

Science Advances

Volumn 2, Issue 6, 2016, Pages

  Singhal, Hari ^a   Greene, Marianne E ^a   Tarulli, Gerard ^b   Zarnke, Allison L ^a   Bourgo, Ryan J ^a   Laine, Muriel ^a   Chang, Ya Fang ^a   Ma, Shihong ^c   Dembo, Anna G ^a   Raj, Ganesh V ^c   Hickey, Theresa E ^b   Tilley, Wayne D ^b   Greene, Geoffrey L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING SITES; BINS; DISEASES; ENDOCRINOLOGY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HORMONES; TUMORS;

CELLULAR PROCESS; COMBINATION THERAPY; DISTAL ENHANCERS; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRANSCRIPTOMES; TUMOR REGRESSION; TUMOR XENOGRAFTS;

GENES;

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CHROMATIN; ESTROGEN RECEPTOR; GESTAGEN; NUCLEOSOME; PROGESTERONE RECEPTOR; PROTEIN BINDING; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BINDING SITE; BREAST NEOPLASMS; CHROMATIN; CLUSTER ANALYSIS; ENHANCER REGION; GENE EXPRESSION PROFILING; GENETICS; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; NUCLEOSOME; NUCLEOTIDE MOTIF; PHENOTYPE; PROGNOSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BINDING SITES; BREAST NEOPLASMS; CHROMATIN; CLUSTER ANALYSIS; ENHANCER ELEMENTS, GENETIC; GENE EXPRESSION PROFILING; GENES, BRCA1; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMANS; MOLECULAR TARGETED THERAPY; NUCLEOSOMES; NUCLEOTIDE MOTIFS; PHENOTYPE; PROGESTINS; PROGNOSIS; PROTEIN BINDING; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84997587752     PISSN: None     EISSN: 23752548     Source Type: Journal    
DOI: 10.1126/sciadv.1501924     Document Type: Article

References (51)

1. N. Heldring, A. Pike, S. Andersson, J. Matthews, G. Cheng, J. Hartman, M. Tujague, A. Ström, E. Treuter, M. Warner, J.-Å. Gustafsson, Estrogen receptors: How do they signal and what are their targets. Physiol. Rev. 87, 905-931 (2007
2. A. R. Daniel, C. R. Hagan, C. A. Lange, Progesterone receptor action: Defining a role in breast cancer. Expert Rev. Endocrinol. Metab. 6, 359-369 (2011
3. C. Brisken, Progesterone signalling in breast cancer: A neglected hormone coming into the limelight. Nat. Rev. Cancer 13, 385-396 (2013
4. C. K. Osborne, M. G. Yochmowitz, W. A. Knight III, W. L. McGuire, The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46 (Suppl. 12), 2884-2888 (1980
5. L.-H. Yang, H.-S. Tseng, C. Lin, L.-S. Chen, S.-T. Chen, S.-J. Kuo, D.-R. Chen, Survival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients. J. Breast Cancer 15, 288-295 (2012
6. X. Cui, R. Schiff, G. Arpino, C. K. Osborne, A. V. Lee, Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J. Clin. Oncol. 23, 7721-7735 (2005
7. A. R. Daniel, A. L. Gaviglio, T. P. Knutson, J. H. Ostrander, A. B. D'Assoro, P. Ravindranathan, Y. Peng, G. V. Raj, D. Yee, C. A. Lange, Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- And estrogen receptor-containing transcription complexes. Oncogene 34, 506-515 (2015
8. C. Ballaré, M. Uhrig, T. Bechtold, E. Sancho, M. Di Domenico, A. Migliaccio, F. Auricchio, M. Beato, Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Mol. Cell. Biol. 23, 1994-2008 (2003
9. S. Giulianelli, J. P. Vaqué, V. Wargon, R. Soldati, S. I. Vanzulli, R. Martins, E. Zeitlin, L. Helguero, C. Lamb, A. A. Molinolo, J. S. Gutkind, C. Lanari, The role of estrogen receptor alpha in breast cancer cell proliferation mediated by progestins. Medicina (B. Aires) 72, 315-320 (2012
10. H. Mohammed, I. A. Russell, R. Stark, O. M. Rueda, T. E. Hickey, G. A. Tarulli, A. A. Serandour, S. N. Birrell, A. Bruna, A. Saadi, S. Menon, J. Hadfield, M. Pugh, G. V. Raj, G. D. Brown, C. D'Santos, J. L. L. Robinson, G. Silva, R. Launchbury, C. M. Perou, J. Stingl, C. Caldas, W. D. Tilley, J. S. Carroll, Progesterone receptor modulates ERa action in breast cancer. Nature 523, 313-317 (2015
11. I. A. Olivotto, P. T. Truong, C. H. Speers, V. Bernstein, S. J. Allan, S. J. Kelly, M. L. Lesperance, Time to stop progesterone receptor testing in breast cancer management. J. Clin. Oncol. 22, 1769-1770 (2004
12. V.-J. Bardou, G. Arpino, R. M. Elledge, C. K. Osborne, G. M. Clark, Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin. Oncol. 21, 1973-1979 (2003
13. M. Dowsett, J. Cuzick, C. Wale, T. Howell, J. Houghton, M. Baum, Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: An hypothesisgenerating study. J. Clin. Oncol. 23, 7512-7517 (2005
14. A. Prat, M. C. U. Cheang, M. Martín, J. S. Parker, E. Carrasco, R. Caballero, S. Tyldesley, K. Gelmon, P. S. Bernard, T. O. Nielsen, C. M. Perou, Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J. Clin. Oncol. 31, 203-209 (2013
15. V. C. Jordan, Tamoxifen: A most unlikely pioneering medicine. Nat. Rev. Drug Discov. 2, 205-213 (2003
16. C. Lanari, V. Wargon, P. Rojas, A. A. Molinolo, Antiprogestins in breast cancer treatment: Are we ready?. Endocr. Relat. Cancer 19, R35-R50 (2012
17. V. Beral; Million Women Study Collaborators, Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362, 419-427 (2003
18. J. E. Rossouw, G. L. Anderson, R. L. Prentice, A. Z. LaCroix, C. Kooperberg, M. L. Stefanick, R. D. Jackson, S. A. Beresford, B. V. Howard, K. C. Johnson, J. M. Kotchen, J. Ockene; Writing Group for the Women?s Health Initiative Investigators, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women?s Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002
19. J. L. Dean, A. K. McClendon, T. E. Hickey, L. M. Butler, W. D. Tilley, A. K. Witkiewicz, E. S. Knudsen, Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle 11, 2756-2761 (2012
20. C. L. Clarke, R. L. Sutherland, Progestin regulation of cellular proliferation. Endocr. Rev. 11, 266-301 (1990
21. K. B. Horwitz, The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer?. Endocr. Rev. 13, 146-163 (1992
22. J. S. Parker, M. Mullins, M. C. U. Cheang, S. Leung, D. Voduc, T. Vickery, S. Davies, C. Fauron, X. He, Z. Hu, J. F. Quackenbush, I. J. Stijleman, J. Palazzo, J. S. Marron, A. B. Nobel, E. Mardis, T. O. Nielsen, M. J. Ellis, C. M. Perou, P. S. Bernard, Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160-1167 (2009
23. N. Howlader, S. F. Altekruse, C. I. Li, V. W. Chen, C. A. Clarke, L. A. G. Ries, K. A. Cronin, US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J. Natl. Cancer Inst. 106, dju055 (2014
24. R. Clarke, M. C. Liu, K. B. Bouker, Z. Gu, R. Y. Lee, Y. Zhu, T. C. Skaar, B. Gomez, K. O'Brien, Y. Wang, L. A. Hilakivi-Clarke, Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22, 7316-7339 (2003
25. J. S. Carroll, C. A. Meyer, J. Song, W. Li, T. R. Geistlinger, J. Eeckhoute, A. S. Brodsky, E. K. Keeton, K. C. Fertuck, G. F. Hall, Q. Wang, S. Bekiranov, V. Sementchenko, E. A. Fox, P. A. Silver, T. R. Gingeras, X. S. Liu, M. Brown, Genome-wide analysis of estrogen receptor binding sites. Nat. Genet. 38, 1289-1297 (2006
26. A. Hurtado, K. A. Holmes, C. S. Ross-Innes, D. Schmidt, J. S. Carroll, FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat. Genet. 43, 27-33 (2011
27. C. S. Ross-Innes, R. Stark, A. E. Teschendorff, K. A. Holmes, H. R. Ali, M. J. Dunning, G. D. Brown, O. Gojis, I. O. Ellis, A. R. Green, S. Ali, S.-F. Chin, C. Palmieri, C. Caldas, J. S. Carroll, Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481, 389-393 (2012
28. A. Migliaccio, D. Piccolo, G. Castoria, M. Di Domenico, A. Bilancio, M. Lombardi, W. Gong, M. Beato, F. Auricchio, Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-Talk with estrogen receptor. EMBO J. 17, 2008-2018 (1998
29. R. Roy, J. Chun, S. N. Powell, BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat. Rev. Cancer 12, 68-78 (2012
30. G. P. Vicent, R. Zaurin, A. S. Nacht, J. Font-Mateu, F. Le Dily, M. Beato, Nuclear factor 1 synergizes with progesterone receptor on the mouse mammary tumor virus promoter wrapped around a histone H3/H4 tetramer by facilitating access to the central hormoneresponsive elements. J. Biol. Chem. 285, 2622-2631 (2010
31. M. A. Augello, T. E. Hickey, K. E. Knudsen, FOXA1: Master of steroid receptor function in cancer. EMBO J. 30, 3885-3894 (2011
32. M. Widschwendter, A. N. Rosenthal, S. Philpott, I. Rizzuto, L. Fraser, J. Hayward, M. P. Intermaggio, C. K. Edlund, S. J. Ramus, S. A. Gayther, L. Dubeau, E. O. Fourkala, A. Zaikin, U. Menon, I. J. Jacobs, The sex hormone system in carriers of BRCA1/2 mutations: A case-control study. Lancet Oncol. 14, 1226-1232 (2013
33. A. J. Poole, Y. Li, Y. Kim, S.-C. J. Lin, W.-H. Lee, E. Y.-H. P. Lee, Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314, 1467-1470 (2006
34. C. Ballaré, G. Castellano, L. Gaveglia, S. Althammer, J. González-Vallinas, E. Eyras, F. Le Dily, R. Zaurin, D. Soronellas, G. P. Vicent, M. Beato, Nucleosome-driven transcription factor binding and gene regulation. Mol. Cell 49, 67-79 (2013
35. G. P. Vicent, R. Zaurin, A. S. Nacht, A. Li, J. Font-Mateu, F. Le Dily, M. Vermeulen, M. Mann, M. Beato, Two chromatin remodeling activities cooperate during activation of hormone responsive promoters. PLOS Genet. 5, e1000567 (2009
36. J. S. Carroll, X. S. Liu, A. S. Brodsky, W. Li, C. A. Meyer, A. J. Szary, J. Eeckhoute, W. Shao, E. V. Hestermann, T. R. Geistlinger, E. A. Fox, P. A. Silver, M. Brown, Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122, 33-43 (2005
37. T. C. Voss, G. L. Hager, Dynamic regulation of transcriptional states by chromatin and transcription factors. Nat. Rev. Genet. 15, 69-81 (2014
38. P. B. Hebbar, T. K. Archer, Chromatin-dependent cooperativity between site-specific transcription factors in vivo. J. Biol. Chem. 282, 8284-8291 (2007
39. M. Pjanic, C. D. Schmid, A. Gaussin, G. Ambrosini, J. Adamick, P. Pjanic, G. Plasari, J. Kerschgens, G. Dietler, P. Bucher, N. Mermod, Nuclear factor I genomic binding associates with chromatin boundaries. BMC Genomics 14, 99 (2013
40. R. Kittler, R. Kittler, J. Zhou, S. Hua, L. Ma, Y. Liu, E. Pendleton, C. Cheng, M. Gerstein, K. P. White, A comprehensive nuclear receptor network for breast cancer cells. Cell Rep. 3, 538-551 (2013
41. C. Curtis, S. P. Shah, S.-F. Chin, G. Turashvili, O. M. Rueda, M. J. Dunning, D. Speed, A. G. Lynch, S. Samarajiwa, Y. Yuan, S. Gräf, G. Ha, G. Haffari, A. Bashashati, R. Russell, S. McKinney; METABRIC Group, A. Langerød, A. Green, E. Provenzano, G. Wishart, S. Pinder, P. Watson, F. Markowetz, L. Murphy, I. Ellis, A. Purushotham, A.-L. Børresen-Dale, J. D. Brenton, S. Tavaré, C. Caldas, S. Aparicio, The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 486, 346-352 (2012
42. The Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012
43. R. Winqvist, G. M. Hampton, A. Mannermaa, G. Blanco, M. Alavaikko, H. Kiviniemi, P. J. Taskinen, G. A. Evans, F. A. Wright, I. Newsham, W. K. Cavanee, Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Res. 55, 2660-2664 (1995
44. I. P. M. Tomlinson, H. Nicolai, E. Solomon, W. F. Bodmer, The frequency and mechanism of loss of heterozygosity on chromosome 11q in breast cancer. J. Pathol. 180, 38-43 (1996
45. B. J. Attardi, J. Burgenson, S. A. Hild, J. R. Reel, In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J. Steroid Biochem. Mol. Biol. 88, 277-288 (2004
46. P. A. Joshi, H. W. Jackson, A. G. Beristain, M. A. Di Grappa, P. A. Mote, C. L. Clarke, J. Stingl, P. D. Waterhouse, R. Khokha, Progesterone induces adult mammary stem cell expansion. Nature 465, 803-807 (2010
47. K. B. Horwitz, W. W. Dye, J. C. Harrell, P. Kabos, C. A. Sartorius, Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc. Natl. Acad. Sci. U.S.A. 105, 5774-5779 (2008
48. J. D. Graham, P. A. Mote, U. Salagame, J. H. van Dijk, R. L. BAlleine, L. I. Huschtscha, R. R. Reddel, C. L. Clarke, DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology 150, 3318-3326 (2009
49. M. M. Centenera, J. L. Gillis, A. R. Hanson, S. Jindal, R. A. Taylor, G. P. Risbridger, P. D. Sutherland, H. I. Scher, G. V. Raj, K. E. Knudsen; Trina Yeadon for the Australian Prostate Cancer BioResource , W. D. Tilley, L. M. Butler, Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clin. Cancer Res. 18, 3562-3570 (2012
50. C. A. Sartorius, S. D. Groshong, L. A. Miller, R. L. Powell, L. Tung, G. S. Takimoto, K. B. Horwitz, New T47D breast cancer cell lines for the independent study of progesterone B- And A-receptors: Only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res. 54, 3868-3877 (1994
51. S. Hua, R. Kittler, K. P. White, Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell 137, 1259-1271 (2009